Austin J. Combest

708 total citations
19 papers, 565 citations indexed

About

Austin J. Combest is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Austin J. Combest has authored 19 papers receiving a total of 565 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in Austin J. Combest's work include Cancer Treatment and Pharmacology (6 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Nanoparticle-Based Drug Delivery (3 papers). Austin J. Combest is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Nanoparticle-Based Drug Delivery (3 papers). Austin J. Combest collaborates with scholars based in United States, Netherlands and France. Austin J. Combest's co-authors include William C. Zamboni, Norman E. Sharpless, Patrick J. Roberts, Jerry Usary, Charles M. Perou, David B. Darr, Kwok‐Kin Wong, John Bisi, Jay C. Strum and Dirk J. Reitsma and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Austin J. Combest

18 papers receiving 557 citations

Peers

Austin J. Combest

ONCOL

PRM

BIOMA

Alessandra Bulotta Italy

Nicoletta Staropoli Italy

Sharon Glaysher United Kingdom

Erkan Yuca United States

Teresa Puértolas Spain

Amin Yaqubie United States

Vincent A. de Weger Netherlands

Hanan Ahmed Wahba Egypt

Peter Cheverton United Kingdom

Andrea Milani Italy

Alessandra Bulotta Italy

Austin J. Combest

406 ×1.4

ONCOL

264 ×1.2

249 ×1.3

PRM

124 ×1.3

52 ×0.7

BIOMA

Citations per year, relative to Austin J. Combest Austin J. Combest (= 1×) peers Alessandra Bulotta

Countries citing papers authored by Austin J. Combest

Since Specialization

Citations

This map shows the geographic impact of Austin J. Combest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Austin J. Combest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Austin J. Combest more than expected).

Fields of papers citing papers by Austin J. Combest

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Austin J. Combest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Austin J. Combest. The network helps show where Austin J. Combest may publish in the future.

Co-authorship network of co-authors of Austin J. Combest

This figure shows the co-authorship network connecting the top 25 collaborators of Austin J. Combest. A scholar is included among the top collaborators of Austin J. Combest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Austin J. Combest. Austin J. Combest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Wit, Ronald de, Stephen J. Freedland, Stéphane Oudard, et al.. (2022). Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. Prostate Cancer and Prostatic Diseases. 26(1). 67–73. 7 indexed citations

Wit, Ronald de, Stephen J. Freedland, Stéphane Oudard, et al.. (2020). 627P Real-world evidence (RWE) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ): Comparison with the randomized clinical study CARD. Annals of Oncology. 31. S518–S518.

Subbiah, Vivek, Juneko E. Grilley‐Olson, Austin J. Combest, et al.. (2017). Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 24(1). 43–51. 82 indexed citations

Bazhenova, Lyudmila, Richard Tran, Juneko E. Grilley‐Olson, et al.. (2017). P1.03-044 Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine. Journal of Thoracic Oncology. 12(11). S1967–S1968. 1 indexed citations

Subbiah, Vivek, Austin J. Combest, Neelesh Sharma, et al.. (2016). Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in pts with advanced solid tumors. Annals of Oncology. 27. vi127–vi127. 1 indexed citations

Combest, Austin J., Juneko E. Grilley‐Olson, Neelesh Sharma, et al.. (2016). Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in patients (pts) with advanced solid tumors. European Journal of Cancer. 69. S118–S119. 3 indexed citations

Combest, Austin J., et al.. (2014). Alternative statistical strategies for biosimilar drug development. Generics and Biosimilars Initiative Journal. 3(1). 13–20. 8 indexed citations

Usary, Jerry, Wei Zhao, David B. Darr, et al.. (2013). Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice. Clinical Cancer Research. 19(17). 4889–4899. 40 indexed citations

Wang, Song, et al.. (2013). Highlighting the challenge of delayed overall survival (OS) curve separation in immunotherapy clinical trials.. Journal of Clinical Oncology. 31(15_suppl). 3009–3009. 3 indexed citations

10.

Combest, Austin J., et al.. (2013). Adult participation in oncology clinical trials by indication, race, and age.. Journal of Clinical Oncology. 31(15_suppl). e17586–e17586. 4 indexed citations

11.

Roberts, Patrick J., Jerry Usary, David B. Darr, et al.. (2012). Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models. Clinical Cancer Research. 18(19). 5290–5303. 107 indexed citations

12.

Roberts, Patrick J., John Bisi, Jay C. Strum, et al.. (2012). Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. JNCI Journal of the National Cancer Institute. 104(6). 476–487. 215 indexed citations

13.

Walko, Christine M., Austin J. Combest, Ivan Spasojević, et al.. (2012). The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemotherapy and Pharmacology. 69(5). 1189–1196. 17 indexed citations

14.

Reitsma, Dirk J. & Austin J. Combest. (2012). Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. Human Vaccines & Immunotherapeutics. 8(8). 1152–1155. 14 indexed citations

15.

Combest, Austin J., Patrick J. Roberts, Patrick M. Dillon, et al.. (2012). Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors. The Oncologist. 17(10). 1303–1316. 27 indexed citations

16.

Zamboni, William C., Austin J. Combest, Julie A. DeLoia, et al.. (2011). Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemotherapy and Pharmacology. 68(5). 1255–1262. 12 indexed citations

17.

Reitsma, Dirk J., et al.. (2011). A novel approach to rituximab biosimilar drug development.. Journal of Clinical Oncology. 29(15_suppl). e13064–e13064. 2 indexed citations

18.

Combest, Austin J., Kristin K. Zorn, Robert P. Edwards, et al.. (2010). Pharmacokinetics (PK) of oxaliplatin (OX) after intraperitoneal (IP) and intravenous (IV) administration in patients with gynecological malignancies.. Journal of Clinical Oncology. 28(15_suppl). 2584–2584. 1 indexed citations

19.

Combest, Wendell L., et al.. (2005). Effects of herbal supplements on the kidney.. PubMed. 25(5). 381–6, 403. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact